1. American Cancer Society. Cancer facts and figures 2013; 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf (Accessed 14 Jun 2013).
2. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
4. Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013;14(2):280–92.
5. GlaxoSmithKline. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist(Tm) (trametinib) tablets, approved by FDA as single-agent therapies [media release]; 29 May 2013. http://www.gsk.com/media/press-releases/2013/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-.html .